New Pre-Surgery step may lower risks for esophageal cancer patients
NCT ID NCT03896399
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a temporary blood-flow restriction procedure (ischemic conditioning) done about two weeks before esophageal cancer surgery. It included 22 patients with artery calcifications who were at higher risk for leaks where the new connection is made. The goal was to see if this pre-treatment is safe and might help reduce serious complications after the main surgery.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
22 people
The number who actually took part.
- Started
-
Nov 2019
- Finished
-
May 2022
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion criteria: * Histologically proven adenocarcinoma (AC) or squamous cell carcinoma (SCC) of the esophagus or gastroesophageal junction (GEJ) * Planned to undergo transthoracic esophagectomy or transhiatal esophagectomy * Preoperative computed tomography (CT) * Vascular arterial changes: "major calcifications" of the thoracic aorta according to the "Uniform calcification score" (UCS) and or a stenosis of the celiac axis according to the "modified NASCET score". (Appendix 1 and 2) (7,17) * ASA I-III * European Clinical Oncology Group (ECOG) performance status of 0,1 or 2 * Age \> 17 * Written informed consent Exclusion criteria: * Not able to undergo study treatment. * Metastatic disease (M1)
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Esophageal cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University Hospital of Cologne
Cologne, North Rhine-Westphalia, 50937, Germany
-
University Medical Center Utrecht
Utrecht, 3584 CX, Netherlands
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Blood proteins may predict who beats esophageal cancer with chemoradiation
- New Antibody-Drug conjugate put to the test against Hard-to-Treat cancers
- Can a direct hit to tumors make immunotherapy work better?
- New antibody aims to preserve immune checkpoint while fighting cancer
- Blood test aims to catch Cancer's return earlier
- Can a guided missile for chemo hit tumors harder and spare healthy tissue?